Flexibility for effective & tolerable control1

Graphic representing dosing up to 48 mg/day with once pill, once-daily AUSTEDO XR. Patients reach 30 mg/day with Titration Kit at the end of Week 4. Most patients were between 36 mg/day and 48 mg/day at the end of the long-term study. Graphic representing dosing up to 48 mg/day with once pill, once-daily AUSTEDO XR. Patients reach 30 mg/day with Titration Kit at the end of Week 4. Most patients were between 36 mg/day and 48 mg/day at the end of the long-term study.
See dosing schedule
Hide dosing schedule

Patients in the pivotal and long-term studies received the AUSTEDO BID formulation.1,2

Image shown is not actual 4-week Titration Kit. Tablets not shown at actual size.

*52% of patients at Week 145.2

Start patients at no cost with the easy-to-use Titration Kit3

Sample with Titration Kit
+ prescribe 36 mg/day for Week 5

AUSTEDO XR 4 Week Titration Kit and 36-mg Rx.

Ask your Sales Rep for samples. Notify
pharmacy if patient has been sampled.

Prescribe Retail Titration Kit
with 30-day Free Trial Voucher applied
+ prescribe 36 mg/day for Week 5

AUSTEDO XR 4 Week Titration Kit and 30-day Free Trial Voucher for new patients.

Pharmacy will dispense prescribed Kit
and apply 30-day Free Trial Voucher.

Titration Kit NDC: 68546-0477-29

Continue titrating weekly until symptom control is effectively and tolerably achieved (48 mg/day maximum dosage).1

Certain restrictions apply. Terms and conditions on AUSTEDOcardform.com.

Physicians reported treatment success starting patients on the 4-week Titration
Kit
3‡

In the real-world START study of the
4-week Titration Kit:

  • >90% of patients adhered to kit
  • Majority of patients reached >24 mg/day by Week 4

Patients & physicians reported3:

  • Treatment success consistent with pivotal studies (PGIC/CGIC)

  • Easy-to-follow titration schedule

  • Overall satisfaction with kit

CGIC, Clinical Global Impression of Change; PGIC, Patient Global Impression of Change.

Treatment success defined as “much improved” or “very much improved” based on PGIC and CGIC.3

§The START study was a non-interventional, real-world study assessing 4-week Titration Kit utilization and treatment
success in 53 patients with tardive dyskinesia and 17 patients with Huntington’s disease chorea, both of similar demographics to the AUSTEDO pivotal studies.3,4

Additional dosing and administration information1
  • Administer AUSTEDO XR in once-daily doses
  • Administer AUSTEDO XR with or without food
  • Swallow AUSTEDO XR whole. Do not crush, chew, or break tablets

Therapeutic equivalence allows switch from AUSTEDO BID to AUSTEDO XR at same daily dose1,3

 

Total Daily Dosage

AUSTEDO XR Strength/QTY

AUSTEDO BID Strength/QTY

Week 1

12 mg

12 mg QD (QTY 7)

6 mg BID (QTY 14)

Week 2

18 mg

18 mg QD (QTY 7)

9 mg BID (QTY 14)

Week 3

24 mg

24 mg QD (QTY 7)

12 mg BID (QTY 14)

Week 4

30 mg

30 mg QD (QTY 7)

9 mg BID (QTY 14)
+ 6 mg BID (QTY 14)

Week 5

36 mg

36 mg QD (QTY 7)

Two 9 mg BID (QTY 28)

Week 6

42 mg

42 mg QD (QTY 7)

12 mg BID (QTY 14)
+ 9 mg BID (QTY 14)

Week 7

48 mg

48 mg QD (QTY 7)

Two 12 mg BID
(QTY 28)

Billing codes

ICD-10 CM Diagnosis Code: G24.01 Tardive Dyskinesia (TD) and G10 Huntington’s Chorea (HD)

AUSTEDO XR Dosage

10-digit NDC

11-digit NDC

4-week Titration Kit

12 mg

Q12 tablet.

18 mg

Q18 tablet.

24 mg

Q24 tablet.

30 mg

Q30 tablet.

36 mg

Q36 mg tablet.

42 mg

Q42 tablet.

48 mg

Q48 tablet.

68546-477-29

68546-471-56

68546-479-56

68546-472-56

68546-473-56

68546-474-56

68546-475-56

68546-476-56

68546-0477-29

68546-0471-56

68546-0479-56

68546-0472-56

68546-0473-56

68546-0474-56

68546-0475-56

68546-0476-56




Specialty Pharmacy Quick Reference Guide

A comprehensive guide for getting patients started on one pill, once-daily AUSTEDO XR.


Additional resources to help with patient access:

REFERENCES: 1. AUSTEDO® XR (deutetrabenazine) extended-release tablets and AUSTEDO® current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc. 2. Hauser RA, Barkay H, Fernandez HH, et al. Long-term deutetrabenazine treatment for tardive dyskinesia is associated with sustained benefits and safety: a 3-year, open-label extension study. Front Neurol. 2022;13:773999. 3. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. 4. Anderson KE, Konings M, Finkbeiner S, et al. Treatment patterns, effectiveness, and satisfaction with deutetrabenazine in Huntington Disease when initiated using a 4-week patient titration kit: interim results of the START Study. Presented at: Huntington Study Group® (HSG) Annual Meeting; November 2-4, 2023; Phoenix, AZ.